2020 Q2 USA Today Clinical Research Supplement

The Clinical Trials Supplement features a variety of informative and timely articles covering topics including the importance clinical trial participation, COVID-19 vaccines and treatments in current development, what to expect from remote and virtual clinical trials, and the powerful role that every person can play in clinical research, featuring insights from an interview with Dr. Marie-Pierre Hellio La Graverand, a leader in drug development for Pfizer.

The ‘Medical Hero’ spotlight cover story shares the experience of Shanelle Gabriel, a poet and singer, who volunteered for a life-changing clinical trial that transformed her lupus treatment. Read the online article.

A Very Special “Thank You” to the supporting organizations:

Pfizer
Merck
Biogen
Bristol Myers Squibb
ORA, Inc.
Segal Trials
SubjectWell
Praxis

CISCRP would like to recognize and extend a ‘Thank You’ to Praxis for donating their pro-bono graphic design expertise to create the advertisement.

View the Advertisement.

2019 Patient Diversity Campaign

CISCRPs inaugural Patient Diversity campaign was implemented in November 2019.  The campaign focuses on sharing educational information about clinical research and highlighting the critical importance of patient diversity within clinical trial participation in order to discover treatments that are effective for all.

CISCRP collaborated with 5 leading publishers serving diverse and minority communities in major cities—Chicago, Los Angeles, New York City, Detroit and Atlanta—to circulate an impactful and meaningful awareness building advertisement (featured to the right).

Five newspapers (print & digital)

The Weekly Citizen (Chicago)

New York Amsterdam (NYC)

Michigan Chronicle (Detroit)

Atlanta Voice (Atlanta)

Excelsior (Los Angeles) (translated to Spanish)

Three additional digital newspapers

Atlanta Daily World

Chicago Defender

News Pittsburgh Courier

 Very Special Thank You to Our 2019 Sponsors

Merck

Janssen

Biogen

Alkermes

Boehringer Ingelheim

Engaging Underserved Communities in Clinical Research

by Stephanie Loomer, CISCRP Staff

Originally published in Clinical Leader. See link below for the complete article.

The importance of clinical trial research in developing treatments and advancing healthcare is widely acknowledged. In 2019 alone, 46,391 study volunteers contributed to clinical trials that resulted in the approval of 48 novel drugs. Of the demographic subpopulations represented, 9% of study volunteers were Black/African American, 9% were Asian, and 18% were Hispanic, highlighting a lack of representation of underserved populations.1 Recently, the FDA recommended broadening eligibility criteria to enhance diversity in clinical trials and therefore better reflect the patients who will be using a drug once it is approved.2

Pharmaceutical companies have begun working to address these disparities in clinical trials. For example, companies such as Sanofi and Eli Lilly have partnered with patient organizations and medical associations to better connect with underserved communities.3 When identifying study sites, both companies include geographic locations with diverse populations in their searches.  Furthermore, Eli Lilly requires that at least two sites be in diverse locations for larger research studies.3 These are a few of the ways that companies can engage a more inclusive group of study volunteers and better understand how the drug will impact the broader target patient population upon approval.

To read the article in its entirety, please visit Clinical Leader.

CISCRP Announces 2nd Annual Virtual Fitness Challenge to Recognize Medical Heroes

Encouraging the clinical research community to come together across the globe to honor medical and healthcare professionals, researchers and study volunteers

Boston, MA | April 2, 2020

On April 15, the Center for Information & Study on Clinical Research Participation (CISCRP) will be initiating the 2nd annual Medical Hero Appreci-a-thon to bring the global clinical research community together to express their appreciation for all “Medical Heroes” – medical and healthcare professionals, researchers and study volunteers.  CISCRP invites the public to participate in this free month-long virtual fitness opportunity.

Participants can share the distance they will go to recognize Medical Heroes by tracking any form of exercise—cycling, running, elliptical, weightlifting, sit-ups, yoga, stair climbing, pet-walking and other physical activities—on the Appreci-a-thon portal. Donations received in support of the virtual fitness challenge provide educational programs designed to help patients and their families navigate the clinical research process.

“Last year, nearly 400 people across industry, research, advocacy, and patient communities participated globally in this virtual appreciation event and the spirit of support and teamwork was inspiring,” said event organizer Justine Holleran. “This year we’re hoping to see an even larger community participating in this virtual fitness challenge to raise awareness about clinical research and its importance to public health.”

“Clinical research education and awareness is even more critical today,” added Ellyn Getz, Associate Director, Development and Community Engagement, at CISCRP.  “Medical, healthcare and research professionals are working tirelessly to provide care and treatment. And patients, their families and the public are seeking information and hope. Join us in showing your support and appreciation for the many dedicated ‘Medical Heroes’ around the world by participating in this virtual fitness challenge!”

The Medical Hero Appreci-a-thon virtual fitness challenge officially starts April 15th and runs through May 15th. Participants can register for free at https://www.ciscrp.org/events/appreci-a-thon.

For additional information, email medicalheroevents@ciscrp.org or visit https://www.ciscrp.org/events/appreci-a-thon

ABOUT CISCRP:

The Center for Information and Study on Clinical Research Participation is an award-winning nonprofit organization dedicated to educating and engaging the public, patients, research and health care professionals as partners in the clinical research process. Since 2003, CISCRP has produced numerous educational and awareness-building programs internationally and has developed a large library of print/digital content to increase health literacy.

Transforming Clinical Trials: Establishing the Rare Disease Advisory Committee

Authored:  Scott Schliebner, SVP, Centers for Rare Diseases & Digital Therapeutics,
PRA Health Sciences

According to Global Genes, the 7,000 distinct types of rare and genetic diseases impact more people than cancer and aids combined.  PRA Health Sciences understands that rare disease clinical development programs are unique, and to be successful, should be approached from an equally innovative perspective.  PRA Health Sciences’ Center for Rare Diseases believes that by working directly with patient advocates offers us the opportunity to better understand the needs of the rare disease community and how we can transform clinical trials to be more effective and accessible for patients.  We are passionate about the role that patients can play to help better design, enhance, and optimize rare disease clinical trials.

The Center for Rare Diseases believes that by partnering with patients, clinical trials are designed and executed more efficiently and with a focus on the items that are most important to patients.  To help achieve this, we formed the Rare Disease Advisory Committee (RDAC), an independent, autonomous group of rare disease patient advocates who are committed to advising and working with PRA to improve the way patients are integrated into the clinical development lifecycle.  The RDAC will examine and explore ways to optimize the drug development process by involving patients, thereby accelerating clinical development and bringing new therapies to patients faster.  Central to this effort will be a focus on how patients and patient advocacy organizations can be impactful partners throughout the entire drug development lifecycle.

The Committee’s initial two focus areas are on (1) developing a Rare Disease Drug Development Patient Engagement Roadmap, and (2) developing a Rare Disease Clinical Trial Engagement Burden Assessment.  We will also be focusing on how patients, and patient advocacy organizations can be made partners throughout this entire process.  We are excited about the efforts of the RDAC and are committed to bringing new therapies to patients faster.

To learn more about the Rare Disease Advisory Committee (RDAC), please visit https://prahs.com/raretogether 

Members have an opportunity to share educational information and new initiatives being introduced about clinical research to patients, caregivers, advocacy organizations and industry. To submit a brief article for consideration, please contact Joan Chambers, jchambers@ciscrp.org

Medical Hero Spotlight: Sandy Morris, ALS Advocate

On January 6, 2018, at the age of 51, Sandy Morris was diagnosed with Amyotrophic Lateral Sclerosis, also known as ALSALS is a progressive nervous system disease that affects the nerve cells in your brain and spinal cord. The disease causes individuals to lose control of the muscles needed to move, speak, eat and breathe. According to the ALS Association, every 90 minutes someone is diagnosed with ALS and someone passes as a result of the disease. There is currently no cure for this debilitating disease. 

Sandy spoke candidly about the effects of ALS, “No one wants their body to trap them.” A mother of 3, she was determined not to give up hope. Following the advice of her best friend, she got involved in a clinical trial at the California Pacific Medical CenterAs part of the trial, she had to undergo bone marrow extraction in order to retrieve stem cells which was followed by a series of infusions and lumbar puncturesAlthough the clinical trial involved invasive procedures, she describes her experience as an overall positive one. Regarding her participation Sandy stressed, “I would rather die trying. I don’t want to just accept my fate.” 

ALS affects everyone differently. Sandy explained, “How we progress is totally unique. I have some friends who can’t talk but can walk, and others who can walk but can’t talk.” For individuals considering participating in a trial, she stressed the importance of being well informed by researching the treatment being tested. Sandy shared her willingness to participate in future clinical trials and encourages others to educate themselves until ALS treatments and cures are found. She encourages others to get involved noting, “That’s the only way we’re going to move forward.” 

 There are currently four medications available to treat ALS. But more research remains to be done to find a cureDespite ALS being a fatal disease, Sandy remains hopeful, “We just need a happy ending and we don’t have one yet.” Her advice for other ALS patients and their loved ones is to remain as positive as possible while learning to live with their disease, something she acknowledges is not an easy thing to do.  

Sandy discussed ways she wants to continue to make a difference including attending FDA meetings to share her experience and influence more efficient, humane clinical trial design. She also stressed the importance of pharmaceutical companies and patients working together to create clinical trials. Her goal is to create hope for the future. Sandy stressed, “I want to make sure that the next 51-year-old mother of three doesn’t have to hear she has ALS period. I want a comma, nothing finalized.” 

New Patient Engagement Insights from the 2019 CISCRP Perceptions & Insights Study

CISCRP hosted a webinar on October 29, 2019 to share the results of the latest 2019 Perceptions & Insights Study. Over 12,450 people (including 3,600 prior study volunteers) from around the world provided their opinions on clinical research. This latest study reveals significant new insights on patient engagement preferences in particular – such as preferences for learning about clinical trials and services which reduce burden the most, the impact of physician recommendations and involvement in clinical trials, and receptivity to emerging models of clinical trials and new technologies.  Critical differences in sentiments by region, race/ethnicity and other demographic variables will also be explored, along with trends and comparisons to prior studies.   

Topics Discussed:

  • How perceptions of clinical research have changed over the years 
  • Preferred patient engagement initiatives
  • Ways to improve clinical research experiences 

Key Takeaways:

  • Continued acknowledgment of the importance of clinical research, but awareness and trust less among those that have never participated  
  • Healthcare provider recommendations continue to be critical to increasing participation in trials 
  • No one size fits all when it comes to various clinical trial models (traditional vs de-centralized) 
  • Study summary and individual results most wanted post-participation
  • Electronic consent forms viewed as easier to understand compared to paper 

Speakers:

  • Ken Getz, Founder and Board Chair at CISCRP and Deputy Director and Professor at Tufts CSDD Tufts University School of Medicine
  • Annick Anderson, Director of Research Services at CISCRP
  • Jasmine Benger, Senior Project Manager of Research Services at CISCRP

To receive invitations to future CISCRP webinars subscribe to our email list.

To collaborate or host a webinar with CISCRP, please email info@ciscrp.org or call the marketing team at 617-725-2750.

Patient Engagement in Clinical Trials

CISCRP and World Courier collaborated to host a webinar on September 24, 2019. This webinar examines the role of patient engagement in recruitment, retention and patient satisfaction in clinical trials. 

Topics Discussed:

  • Patient Feedback on Clinical Trial Participation
  • What do Patients Want and how can we Support Them?
  • Value of Investing in Patient Engagement
  • What is Direct-to-Patient (DtP) Logistics?
  • DtP Case Study: Collaborative Project Setup
  • What are Organizations Doing Now? What are the Next Steps?

Key Takeaways:

  • There is no ‘one-size fits all’ approach to patient engagement – options are key!
  • Helping advance science and treatment, the ability to access information about their health and condition, and the amount of care and attention they received while enrolled are some of the top ‘likes’ among clinical trial volunteers

Speakers:

  • Jasmine Benger, Senior Project Manager, Research Services, CISCRP
  • Alex Guite, Vice President, Strategy and Services, World Courier
  • Mike Sweeney, Senior Director, Patient Centric Logistics, World Courier

To receive invitations to future CISCRP webinars subscribe to our email list.

To collaborate or host a webinar with CISCRP, please email info@ciscrp.org or call the marketing team at 617-725-2750.

Supporter Spotlight: Biogen

Biogen has played, and continues to play, an active role in supporting CISCRP’s mission to educate patient communities about clinical trials. A host sponsor of our upcoming AWARE for All programs in Atlanta and Phoenix, their support has further demonstrated their commitment to improving disparities in clinical research literacy among diverse and underserved communities and building a foundation of support and access among minority health care providers.

Biogen’s work with CISCRP also extends to our Perceptions & Insights study, Health Communication Services, as well as Patient Advisory Boards (PABs) which further showcases their patient-focused culture and mission to deliver innovative therapies for people living with neurological and neurodegenerative diseases.

We met with Murray Abramson, MD, Vice President of Global Clinical Operations at Biogen and a major champion of these engagement efforts. Murray highlighted the importance of “stepping into the shoes of patients” to gain a better understanding of what matters to them. Murray shared one of his motivations with us, “It is absolutely imperative to reach out to people, particularly in disease areas where there aren’t good treatment options or perhaps not any treatment options at all.”

Biogen has also developed a number of meaningful, impactful, internal programs to promote patient engagement among staff. The team’s Tree of Hope, dedicated to Carol Seider’s memory, was prominently displayed with placards representing staff motivations on ways in which they can support patients around the world. Carol Seider lived her life dedicated to finding treatments and cures for patients in her role as Senior Director of Global Clinical Operations. She helped inspire Biogen to seek new ways to amplify the voice of patients in clinical research.

In addition, Biogen hosts an annual Patient Engagement Day to bring employees together across R&D to raise awareness about Biogen’s patient engagement efforts and ways to implement meaningful initiatives as a part of department-wide activities. Ken Getz shared CISCRP’s Perceptions & Insights data at a recent Patient Engagement Day that focused on building a sustainable and stronger engagement with underrepresented patient populations for clinical trials.

CISCRP is grateful for Biogen’s support of numerous patient engagement activities, which help to raise awareness, empower individuals and their families with education to allow for informed decision-making processes, and improve overall clinical trial experiences.

Written by Ellyn Getz, Associate Director of Development & Community Engagement

From the Editor

Dear Readers, 

Autumn is here and in New England, there is a crisp coolness in the air along with the leaves starting to turn colors of red, yellow and orange.  A beautiful time of year and a sign that 2019 is fast approaching its close.  Like many organizations, CISCRP is focusing and spear-heading several different initiatives with an eye towards 2020 planning.   

In this edition, Leah Crocker, our Medical Hero Spotlight, shares her journey with Lupus and Raynaud’s phenomenon, a common symptom of Lupus. Leah’s clinical trial journey began when relocating to a warmer climate, Georgia, and connected with a Rheumatologist, who encouraged her to participate in a clinical trial. 

In addition to Leah’s inspiring story, our Q3 newsletter features a variety of exciting articles covering key programs, events and initiatives supporting our mission of building awareness and education among diverse communities. 

The initiatives are in full motion with the AWARE for ALL events being hosted in Atlanta and Phoenix, the Journey to Better Health mobile, interactive exhibit ‘on wheels,’ to the 2019 Perceptions and Insights study where results are in and analyzed.  We are continually working with industry professionals on producing Trial Result Summaries to offer to patients who participated in clinical studies to help them understand the study’s outcome.  

A new initiative underway that we are very excited about is expanding clinical trial awareness and the importance of participation to diverse and underserved minority communities.  This new media awareness campaign is in addition to our annual National Clinical Trial Outreach and Awareness Initiative with the USA Today Supplement.   

I invite you to read the brief articles to learn moreshare your comments and to participate in the media awareness campaign.  

If you are in search of educational materials about clinical trial participation, please visit the CISCRP Store for brochures, posters and videos that can be used to educate patients about clinical research. Brochures may also be co-branded for use at research sites, healthcare forums, educational workshops or other events. Please contact me, jchambers@ciscrp.org, for details.  

As we enjoy Autumn, and all that it brings, we welcome the opportunity to assist you in further building educational and awareness programs around clinical trials to all communities.  Please contact us as you work on developing your end of year 2019 and 2020 plans.  

We look forward to seeing you at the upcoming industry events.  Thank you for your continued support.  

Warm regards, 


Joan A. Chambers 
Senior Director, Marketing & Outreach